OBJECTIVES: To determine the benefits and risks of a non-steroidal anti-inflammatory drug (NSAID) as prophylaxis for ectopic bone formation in patients undergoing total hip replacement (or revision) surgery. DESIGN: Double blind randomised placebo controlled clinical trial, stratified by treatment site and surgery (primary or revision). SETTING: 20 orthopaedic surgery centres in Australia and New Zealand. PARTICIPANTS: 902 patients undergoing elective primary or revision total hip replacement surgery. INTERVENTION: 14 days' treatment with ibuprofen (1200 mg daily) or matching placebo started within 24 hours of surgery. MAIN OUTCOME MEASURES: Changes in self reported hip pain and physical function 6 to 12 months after surgery (Western Ontario and McMaster University Arthritis index). RESULTS: There were no significant differences between the groups for improvements in hip pain (mean difference -0.1, 95% confidence interval -0.4 to 0.2, P = 0.6) or physical function (-0.1, -0.4 to 0.2, P = 0.5), despite a decreased risk of ectopic bone formation (relative risk 0.69, 0.56 to 0.83) associated with ibuprofen. There was a significantly increased risk of major bleeding complications in the ibuprofen group during the admission period (2.09, 1.00 to 4.39). CONCLUSIONS: These data do not support the use of routine prophylaxis with NSAIDs in patients undergoing total hip replacement surgery. TRIAL REGISTRATION: NCT00145730.
RCT Entities:
OBJECTIVES: To determine the benefits and risks of a non-steroidal anti-inflammatory drug (NSAID) as prophylaxis for ectopic bone formation in patients undergoing total hip replacement (or revision) surgery. DESIGN: Double blind randomised placebo controlled clinical trial, stratified by treatment site and surgery (primary or revision). SETTING: 20 orthopaedic surgery centres in Australia and New Zealand. PARTICIPANTS: 902 patients undergoing elective primary or revision total hip replacement surgery. INTERVENTION: 14 days' treatment with ibuprofen (1200 mg daily) or matching placebo started within 24 hours of surgery. MAIN OUTCOME MEASURES: Changes in self reported hip pain and physical function 6 to 12 months after surgery (Western Ontario and McMaster University Arthritis index). RESULTS: There were no significant differences between the groups for improvements in hip pain (mean difference -0.1, 95% confidence interval -0.4 to 0.2, P = 0.6) or physical function (-0.1, -0.4 to 0.2, P = 0.5), despite a decreased risk of ectopic bone formation (relative risk 0.69, 0.56 to 0.83) associated with ibuprofen. There was a significantly increased risk of major bleeding complications in the ibuprofen group during the admission period (2.09, 1.00 to 4.39). CONCLUSIONS: These data do not support the use of routine prophylaxis with NSAIDs in patients undergoing total hip replacement surgery. TRIAL REGISTRATION: NCT00145730.
Authors: J R Lieberman; F Dorey; P Shekelle; L Schumacher; B J Thomas; D J Kilgus; G A Finerman Journal: J Bone Joint Surg Am Date: 1996-06 Impact factor: 5.284
Authors: D Henry; L L Lim; L A Garcia Rodriguez; S Perez Gutthann; J L Carson; M Griffin; R Savage; R Logan; Y Moride; C Hawkey; S Hill; J T Fries Journal: BMJ Date: 1996-06-22
Authors: R Likar; W Jaksch; T Aigmüller; M Brunner; T Cohnert; J Dieber; W Eisner; S Geyrhofer; G Grögl; F Herbst; R Hetterle; F Javorsky; H G Kress; O Kwasny; S Madersbacher; H Mächler; R Mittermair; J Osterbrink; B Stöckl; M Sulzbacher; B Taxer; B Todoroff; A Tuchmann; A Wicker; A Sandner-Kiesling Journal: Schmerz Date: 2017-10 Impact factor: 1.107
Authors: Sebastian Winkler; Hans-Robert Springorum; Tobias Vaitl; Martin Handel; Sabine Barta; Victoria Kehl; Benjamin Craiovan; Joachim Grifka Journal: Int Orthop Date: 2016-01-04 Impact factor: 3.075